Metastatic Hormone-Sensitive Prostate Cancer: Data From ENZAMET and ARCHES

Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.

Related Keywords

,Key Updates ,Metastatic Prostate Cancer Treatment ,Hormone Sensitive Prostate Cancer ,Data From ,Prostate Cancer ,Metastatic Hormone Sensitive Prostate Cancer ,Mhspc ,Enzamet Trial ,Enzamet Study ,Arches Trial ,Arches Study ,Enzalutamide ,Overall Survival ,Survival Data ,High Volume Disease ,Novel Therapy ,